Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

NCT04102618 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT04102618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04102618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
Lead sponsor
Oncolytics Biotech
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2019
Completion date
April 20, 2022
Enrollment
26 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer